Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Bone Research

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1528962

Risk factors for glucocorticoid induced osteoporosis in young adults

Provisionally accepted
Helena  FlorezHelena Florez1*Josep  Lluis CarrascoJosep Lluis Carrasco2Martina  BarberáMartina Barberá2José  Hernández-RodríguezJosé Hernández-Rodríguez1Africa  MuxiAfrica Muxi1Anastasia  MocritcaiaAnastasia Mocritcaia1Sergio  Prieto-GonzálezSergio Prieto-González1Maria  C CidMaria C Cid1Ana  MonegalAna Monegal1Núria  GuañabensNúria Guañabens1Pilar  PerisPilar Peris1
  • 1Hospital Clinic of Barcelona, Barcelona, Spain
  • 2University of Barcelona, Barcelona, Catalonia, Spain

The final, formatted version of the article will be published soon.

Introduction: Glucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age. The aim of the study was to analyse if factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF) differ according to age.Methods: 127 patients on chronic glucocorticoid (GC) treatment were analysed, including GC doses and duration, disease activity, FF, anthropometric data, bone metabolism parameters (including sex steroids), bone mineral density, trabecular bone score, and radiologic vertebral fractures; defining GIOP as densitometric osteoporosis and/or FF. Young subjects (<50 years old) were compared with those ≥50 years for risk factors of GIOP and FF.Results: GIOP prevalence was similar in both age groups: <50 (n=36) 44.4% vs. 46.1% ≥50 years (n=91). Five subjects <50 (13.9%) and 30 ≥50 years (33%) presented FF (p=0.046).Having a higher body mass index (BMI), disease activity was a differential risk factor for FF in young subjects, whereas hypogonadism was a risk factor independent of age.Conclusions: More than 40% of young subjects on chronic GC therapy had GIOP. A higher BMI and disease activity and particularly, hypogonadism seem to be factors related to FF development in these subjects. Evaluation of these risk factors can improve the identification of young subjects at increased risk of fracture.

Keywords: Glucocorticoid-induced osteoporosis, Hypogonadism, Young patients, fragility fracture, Risk factors

Received: 15 Nov 2024; Accepted: 19 Jun 2025.

Copyright: © 2025 Florez, Carrasco, Barberá, Hernández-Rodríguez, Muxi, Mocritcaia, Prieto-González, Cid, Monegal, Guañabens and Peris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Helena Florez, Hospital Clinic of Barcelona, Barcelona, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.